1. A 51-year-old man with no prior history of diabetes or impaired fasting glucose receives a deceased-donor kidney transplant. His maintenance regimen consists of tacrolimus, mycophenolate mofetil (MMF), and prednisone 10 mg/day. At his 3-month visit his fasting glucose is 174 mg/dL and his HbA1c has risen from a pre-transplant value of 5.3% to 7.1%. He has gained 4 kg since transplant. His tacrolimus trough is 8.6 ng/mL. Which of the following best identifies the most likely primary drug responsible for his new-onset diabetes and the mechanism by which it causes this complication?
A) Mycophenolate mofetil is the most likely cause; MPA (mycophenolic acid) inhibits IMPDH in pancreatic beta cells, depleting GTP required for insulin granule exocytosis and reducing glucose-stimulated insulin secretion in a dose-dependent manner
B) The weight gain since transplant indicates that his new-onset diabetes is attributable entirely to increased caloric intake and physical deconditioning in the post-operative period; no immunosuppressant is primarily responsible and no medication adjustment is warranted
C) Prednisone is the sole cause of new-onset diabetes after transplantation in this patient; corticosteroids cause diabetes exclusively through peripheral insulin resistance mediated by GLUT4 transporter downregulation in skeletal muscle, and tacrolimus has no independent diabetogenic effect
D) Tacrolimus is the most likely primary contributor; it causes new-onset diabetes after transplantation (NODAT) in approximately 10 to 20% of recipients by impairing pancreatic beta-cell insulin secretion through its FKBP-12 (FK-binding protein 12) pathway in beta cells, and is significantly more diabetogenic than cyclosporine, which causes NODAT in only 5 to 10% of recipients
E) The combination of tacrolimus and MMF produces a synergistic diabetogenic effect through simultaneous inhibition of beta-cell calcineurin and beta-cell IMPDH; neither drug alone would cause diabetes at these doses, and dose reduction of both agents simultaneously is required before initiating any antidiabetic therapy
ANSWER: D
Rationale:
New-onset diabetes after transplantation (NODAT) is a well-recognized complication of calcineurin inhibitor-based immunosuppression, and tacrolimus is significantly more diabetogenic than cyclosporine. Tacrolimus causes NODAT in approximately 10 to 20% of recipients compared to 5 to 10% with cyclosporine, likely because tacrolimus more potently impairs insulin secretion from pancreatic beta cells through its FKBP-12 pathway. The calcineurin-NFAT signaling axis is active in beta cells and plays a role in insulin gene transcription and secretion; tacrolimus-mediated calcineurin inhibition in beta cells reduces glucose-stimulated insulin secretion. While corticosteroids and weight gain both contribute to post-transplant hyperglycemia through peripheral insulin resistance, the drug most specifically and potently associated with NODAT is tacrolimus. In this patient with a therapeutic tacrolimus trough and no prior glucose abnormality, tacrolimus is the primary pharmacological contributor. Management includes glucose monitoring at every visit, HbA1c every 3 months, consideration of tacrolimus dose minimization or conversion to cyclosporine in selected patients, and initiation of antidiabetic therapy if glucose targets are not met.
Option A: Option A is incorrect: MMF does not cause diabetes. MPA inhibits IMPDH in lymphocytes — not in pancreatic beta cells — and there is no established mechanism by which MMF impairs insulin secretion or causes NODAT.
Option B: Option B is incorrect: while weight gain and deconditioning contribute to insulin resistance post-transplant, attributing NODAT entirely to lifestyle factors without recognizing the significant pharmacological contribution of tacrolimus would be clinically incorrect and would fail to address a modifiable drug-related cause.
Option C: Option C is incorrect: corticosteroids do contribute to post-transplant hyperglycemia primarily through peripheral insulin resistance and hepatic gluconeogenesis stimulation, but tacrolimus has a well-established independent diabetogenic effect through beta-cell calcineurin inhibition that is distinct from and additive with steroid effects. Stating that tacrolimus has no independent diabetogenic effect is pharmacologically incorrect.
Option E: Option E is incorrect: MMF does not cause NODAT through beta-cell IMPDH inhibition, and the two drugs do not produce synergistic diabetogenicity. Tacrolimus is the primary pharmacological driver of NODAT in this regimen.
2. A 38-year-old kidney transplant recipient on stable tacrolimus (trough 8.2 ng/mL) is diagnosed with active pulmonary tuberculosis and started on rifampin-based combination therapy. Five days later his tacrolimus trough is 1.8 ng/mL despite unchanged dosing. He is asymptomatic but a surveillance biopsy performed for the falling level shows early tubulointerstitial inflammation consistent with subclinical rejection. Which of the following best describes the mechanism underlying the trough drop and the required management?
A) Rifampin is a potent inducer of CYP3A4 and P-glycoprotein through activation of the pregnane X receptor (PXR), dramatically accelerating tacrolimus metabolism and intestinal efflux; tacrolimus AUC (total drug exposure) falls by 70 to 90%, requiring a 3 to 5-fold dose increase with twice-weekly trough monitoring during both initiation and discontinuation of rifampin, and substitution with rifabutin should be considered as a weaker inducer alternative
B) Rifampin chelates tacrolimus in the gastrointestinal tract, forming an insoluble complex that prevents absorption; separating tacrolimus and rifampin doses by 4 hours restores normal tacrolimus absorption without requiring dose adjustment
C) Rifampin competitively inhibits tacrolimus binding to FKBP-12, reducing the drug's immunosuppressive potency without changing its plasma concentration; the measured trough appears low because the assay detects total tacrolimus including FKBP-12-unbound drug, but functionally active drug is unchanged
D) Rifampin inhibits renal tubular secretion of tacrolimus metabolites, causing them to accumulate and competitively reduce parent drug binding to erythrocytes; the whole blood trough falsely decreases due to metabolite competition for erythrocyte binding sites while true free drug concentration is unchanged
E) Rifampin activates intestinal mast cells to release histamine, which upregulates P-glycoprotein expression in the intestinal epithelium; increased P-gp efflux reduces tacrolimus absorption, and antihistamine pretreatment before each tacrolimus dose is the appropriate management
ANSWER: A
Rationale:
Rifampin (rifampicin) is one of the most potent inducers of both CYP3A4 and P-glycoprotein (P-gp) in clinical use, acting through activation of the pregnane X receptor (PXR) — a nuclear receptor that transcriptionally upregulates CYP3A4, CYP3A5, and MDR1 (P-gp). Tacrolimus is a substrate of both CYP3A4 (its primary metabolic enzyme) and P-gp (intestinal efflux transporter). When rifampin is co-administered, dramatically accelerated CYP3A4-mediated hepatic and intestinal metabolism plus increased P-gp-mediated intestinal efflux reduce tacrolimus AUC by approximately 70 to 90%. The observed drop from 8.2 to 1.8 ng/mL — a more than 4-fold reduction — is consistent with this interaction magnitude. Management requires a 3 to 5-fold tacrolimus dose increase, with twice-weekly trough monitoring because the induction effect develops over days and reverses over days to weeks upon rifampin discontinuation. Wherever feasible, rifabutin — a significantly weaker CYP3A4/P-gp inducer — should be substituted for rifampin in transplant recipients with tuberculosis.
Option B: Option B is incorrect: rifampin does not chelate tacrolimus. Chelation interactions are characteristic of polyvalent cations (calcium, magnesium, iron, aluminum) binding fluoroquinolones or tetracyclines. Rifampin's interaction with tacrolimus is entirely enzymatic — CYP3A4 and P-gp induction — not physicochemical binding in the gut.
Option C: Option C is incorrect: rifampin does not compete with tacrolimus for FKBP-12 binding. Rifampin has no pharmacodynamic interaction at the FKBP-12 or calcineurin level. The measured trough drop reflects a genuine reduction in total tacrolimus blood concentrations, not an assay artifact.
Option D: Option D is incorrect: tacrolimus is eliminated primarily through hepatic CYP3A4 metabolism and biliary excretion — not renal tubular secretion. Rifampin does not affect erythrocyte binding of tacrolimus through metabolite competition.
Option E: Option E is incorrect: rifampin does not activate intestinal mast cells or induce P-gp through histamine release. PXR-mediated transcriptional upregulation is the mechanism of rifampin enzyme induction, and antihistamine pretreatment has no effect on this interaction.
3. A 44-year-old woman is 16 days post-kidney transplant. Her serum creatinine, which had improved to 1.3 mg/dL by day 10, has now risen to 2.1 mg/dL over the past 4 days. She is afebrile with no graft tenderness. Her tacrolimus trough is 18.4 ng/mL (target 8 to 12 ng/mL). Urinalysis shows no pyuria or casts. The transplant team reduces her tacrolimus dose; 72 hours later her creatinine returns to 1.4 mg/dL. Which of the following best explains the mechanism responsible for the creatinine rise and its rapid reversibility with dose reduction?
A) The supratherapeutic tacrolimus level caused chronic interstitial fibrosis and tubular atrophy through TGF-β upregulation; the creatinine improvement after dose reduction indicates that early fibrotic changes are partially reversible within the first 3 weeks post-transplant when the fibrotic response is still in the inflammatory phase
B) The elevated tacrolimus caused acute cellular rejection by paradoxically activating calcineurin at supratherapeutic concentrations; dose reduction to therapeutic levels restored appropriate calcineurin inhibition and reversed the rejection-mediated creatinine rise
C) Supratherapeutic tacrolimus caused acute functional nephrotoxicity through dose-dependent afferent arteriolar vasoconstriction — driven by increased endothelin and thromboxane and decreased prostaglandins — reducing GFR in a hemodynamically reversible manner; dose reduction restored arteriolar tone and GFR within days
D) The tacrolimus trough of 18.4 ng/mL caused thrombotic microangiopathy (TMA) by inducing severe endothelial injury in glomerular capillaries; the rapid creatinine recovery after dose reduction confirms TMA as the diagnosis, since TMA resolves within 72 hours of stopping the offending drug
E) The creatinine rise reflects delayed graft function from surgical ischemia-reperfusion injury that coincidentally occurred at the same time as a tacrolimus level peak; the trough level is unrelated to the creatinine rise and the recovery reflects natural resolution of ischemia-reperfusion injury independent of dose reduction
ANSWER: C
Rationale:
The acute functional mechanism of CNI nephrotoxicity is hemodynamic: supratherapeutic tacrolimus concentrations increase renal afferent arteriolar vasoconstrictors (endothelin, thromboxane A2) and decrease vasodilatory prostaglandins, causing dose-dependent constriction of the afferent arteriole and reduced glomerular capillary pressure and filtration rate. Because the mechanism is vascular rather than structural, the GFR reduction is fully reversible when drug concentrations fall — as demonstrated by the creatinine returning to near-baseline within 72 hours of dose reduction in this patient. This rapid, trough-correlated, reversible creatinine rise is the clinical signature of acute functional CNI nephrotoxicity and is distinguished from chronic structural nephropathy (which takes months to years to develop, shows histological fibrosis on biopsy, and does not reverse with dose reduction).
Option A: Option A is incorrect: chronic structural CNI nephropathy with interstitial fibrosis and tubular atrophy develops over years of cumulative CNI exposure — not 16 days post-transplant. Fibrotic changes are irreversible and do not recover within 72 hours of dose reduction; this time course and reversibility definitively identify the mechanism as acute functional (hemodynamic), not chronic structural.
Option B: Option B is incorrect: supratherapeutic tacrolimus concentrations do not paradoxically activate calcineurin. Higher tacrolimus levels produce greater, not lesser, calcineurin inhibition. The creatinine rise is nephrotoxic — not rejection-mediated — and the rapid reversal with dose reduction is characteristic of hemodynamic toxicity, not treatment of rejection.
Option D: Option D is incorrect: tacrolimus-induced TMA is a rare but serious complication that presents with microangiopathic hemolytic anemia, thrombocytopenia, and schistocytes on blood smear — not simply as an isolated creatinine rise. TMA does not resolve within 72 hours of dose reduction; it typically requires plasma exchange and often drug discontinuation with switch to an alternative immunosuppressant.
Option E: Option E is incorrect: ischemia-reperfusion injury causing delayed graft function typically manifests in the first days post-transplant — not at 16 days in a patient whose creatinine had already improved to 1.3 mg/dL. The temporal correlation between the supratherapeutic trough and the creatinine rise, and the rapid recovery upon dose reduction, establish causation rather than coincidence.
4. A 31-year-old South Korean woman with a kidney transplant was started on azathioprine 150 mg/day six weeks ago. Pre-treatment TPMT genotyping showed wild-type activity (TPMT*1/*1). She now presents with fever, mouth sores, and fatigue. Laboratory results show WBC 0.9 × 10⁹/L, hemoglobin 8.4 g/dL, and platelets 62 × 10⁹/L. No allopurinol or other xanthine oxidase inhibitors are on her medication list. The hematologist asks the transplant pharmacist why this patient developed severe myelosuppression despite a normal TPMT genotype. Which of the following best explains the most likely pharmacogenomic mechanism?
A) Wild-type TPMT genotype results are unreliable in patients of East Asian ancestry because the TPMT*1 allele in Korean populations encodes a structurally distinct enzyme isoform with reduced substrate affinity for 6-MP that is not detected by standard TPMT activity assays
B) The patient likely has an undetected CYP3A5*1 allele that diverts azathioprine metabolism toward a hepatotoxic pathway, producing bone marrow-toxic intermediates that are not thioguanine nucleotides and are unaffected by TPMT genotype
C) Wild-type TPMT activity at the time of testing is irrelevant because TPMT enzyme activity undergoes progressive autoimmune inactivation during the first 4 to 8 weeks of azathioprine therapy in patients with autoimmune-prone genotypes; her TPMT activity has fallen to near-zero since the pre-treatment test was performed
D) A concurrent viral infection — most likely EBV reactivation triggered by immunosuppression — has caused bone marrow suppression independent of azathioprine; the myelotoxicity is coincidental and azathioprine dosing is not responsible
E) TPMT genotyping alone is insufficient to predict thiopurine myelotoxicity in patients of East and Southeast Asian ancestry; NUDT15 (nudix hydrolase 15) variant alleles — particularly prevalent in Korean, Chinese, and Southeast Asian populations — impair TGN triphosphate inactivation and predict severe thiopurine-induced myelosuppression independently of TPMT status; this patient likely carries a NUDT15 poor-metabolizer variant that was not tested
ANSWER: E
Rationale:
This vignette illustrates the critical clinical lesson that TPMT genotyping alone does not fully characterize thiopurine myelotoxicity risk in patients of East and Southeast Asian ancestry. NUDT15 encodes nudix hydrolase 15, which inactivates thioguanine nucleotide triphosphates (TGN-TP) — the DNA-toxic metabolites produced by the HGPRT anabolic pathway. NUDT15 variant alleles (particularly NUDT15*2 and NUDT15*3) are substantially more prevalent in East and Southeast Asian populations than in European populations: approximately 10 to 15% of East Asians carry at least one variant allele, compared to less than 1% of Europeans. A NUDT15 poor-metabolizer cannot efficiently hydrolyze TGN-TP, allowing these cytotoxic metabolites to accumulate in hematopoietic progenitor cells and cause severe myelosuppression at doses that would be safe in patients with normal NUDT15 function. In a Korean patient who develops unexpected severe pancytopenia at standard azathioprine dosing despite wild-type TPMT, NUDT15 poor-metabolizer status is the most likely explanation. CPIC guidelines now recommend testing both TPMT and NUDT15 before initiating thiopurine therapy, particularly in patients of East or Southeast Asian ancestry. Azathioprine must be discontinued and NUDT15 testing performed; alternative immunosuppression (such as MMF) should be substituted.
Option A: Option A is incorrect: TPMT*1 genotyping by sequencing detects the actual nucleotide sequence of both alleles and is not population-specifically inaccurate for Korean patients. The assay reliability argument is not an established pharmacogenomic limitation.
Option B: Option B is incorrect: CYP3A5 metabolizes tacrolimus — not azathioprine. Azathioprine and its thiopurine metabolites are not substrates of CYP3A5, and this allele has no established role in thiopurine myelotoxicity.
Option C: Option C is incorrect: TPMT enzyme activity does not undergo progressive autoimmune inactivation during azathioprine therapy. TPMT activity is genetically determined and stable; it does not fall over the course of treatment.
Option D: Option D is incorrect: while EBV reactivation can cause cytopenias, attributing severe pancytopenia to coincidental viral infection without investigating the pharmacogenomic explanation — particularly in a high-risk ancestral group — would represent a diagnostic error. The clinical presentation of severe pancytopenia at 6 weeks of azathioprine in a TPMT wild-type patient of East Asian ancestry is the textbook presentation of undetected NUDT15 deficiency.
5. A 47-year-old kidney transplant recipient on tacrolimus, mycophenolate mofetil (MMF) 1.5 g twice daily, and prednisone reports persistent nausea, crampy abdominal pain, and 4 to 6 loose stools per day beginning 3 weeks after transplant. His tacrolimus trough is 7.8 ng/mL. Stool studies for Clostridioides difficile, CMV colitis, and enteric pathogens are all negative. His creatinine is stable. Which of the following represents the most appropriate initial management of his gastrointestinal symptoms?
A) Initiate loperamide 2 mg after each loose stool and continue MMF at the current dose; gastrointestinal symptoms from MMF are invariably transient and resolve within 6 to 8 weeks without dose modification in all patients
B) Reduce the MMF dose or switch to the enteric-coated mycophenolate sodium formulation (Myfortic), which releases MPA in the duodenum rather than the stomach and may reduce upper gastrointestinal adverse effects; alternatively, splitting the same total daily dose into three-times-daily rather than twice-daily dosing can reduce peak MPA concentrations and improve GI tolerability — all while monitoring for any change in creatinine suggesting reduced immunosuppression
C) Discontinue MMF immediately and switch to azathioprine without dose reduction; MMF-induced colitis always requires permanent discontinuation because rechallenge invariably produces a more severe recurrence and azathioprine has no gastrointestinal adverse effects
D) Increase the prednisone dose to 40 mg/day; high-dose corticosteroids will suppress the MMF-induced intestinal inflammation through NF-κB transrepression and allow the gastrointestinal mucosa to heal while maintaining the MMF dose for adequate immunosuppression
E) Perform urgent colonoscopy with biopsies before any medication adjustment; MMF-induced colitis cannot be distinguished from CMV colitis, graft-versus-host disease, or inflammatory bowel disease without histological confirmation, and empirical dose reduction is contraindicated until a tissue diagnosis is established
ANSWER: B
Rationale:
Gastrointestinal adverse effects — nausea, vomiting, diarrhea, abdominal cramping — are the most common toxicity of MMF, occurring in 30 to 45% of patients and representing a significant cause of poor adherence. The GI effects are dose-dependent and related to high peak MPA concentrations in the gut. Several management strategies reduce GI toxicity while preserving adequate immunosuppression. First, dose reduction (for example from 3 g/day to 2 g/day) reduces peak MPA concentrations and often improves symptoms. Second, switching to enteric-coated mycophenolate sodium (Myfortic, EC-MPS) releases MPA in the duodenum rather than the stomach, potentially reducing upper GI symptoms in some patients. Third, changing from twice-daily to three-times-daily dosing of the same total daily dose blunts peak concentrations. Any of these strategies should be accompanied by creatinine monitoring to detect any reduction in immunosuppressive efficacy. In this patient, with confirmed negative infectious workup, dose-dependent MMF GI toxicity is the most likely diagnosis and the above adjustments are the evidence-based first-line approach.
Option A: Option A is incorrect: loperamide is a reasonable symptomatic measure but using it to simply continue the current MMF dose without addressing the underlying dose-related GI toxicity is not best practice. GI symptoms from MMF are not invariably self-limiting within 6 to 8 weeks in all patients — many require dose modification.
Option C: Option C is incorrect: MMF-induced GI symptoms do not mandate permanent discontinuation. Dose reduction, formulation switch, or dosing frequency adjustment typically improve symptoms without requiring permanent drug withdrawal. Azathioprine also has hepatotoxic and myelosuppressive adverse effects; the claim that it has no GI adverse effects is incorrect.
Option D: Option D is incorrect: increasing prednisone to 40 mg/day would add substantial metabolic, bone, and infectious risk without addressing the dose-dependent mechanism of MMF GI toxicity. Corticosteroids are not the appropriate management for MMF GI adverse effects.
Option E: Option E is incorrect: urgent colonoscopy is not required before any medication adjustment in a patient whose GI symptoms began shortly after MMF initiation and whose infectious workup is already negative. Infectious etiologies have been excluded, and the temporal relationship with MMF initiation makes dose-dependent drug toxicity the working diagnosis. Empirical MMF dose adjustment is both appropriate and standard of care in this context.
6. A 39-year-old woman with a kidney transplant performed 18 months ago presents with a 7-week history of right groin and hip pain, worse with weight-bearing and at rest. She is maintained on tacrolimus, MMF, and prednisone 7.5 mg/day. Plain radiographs of the right hip are reported as normal by radiology. She has no history of trauma, sickle cell disease, or alcohol use. Her creatinine is stable and tacrolimus trough is within target range. What is the most appropriate next diagnostic step?
A) Bone density scan (DXA) of the lumbar spine and hip; the most likely diagnosis is steroid-induced osteoporosis causing an insufficiency fracture of the femoral neck that is below the detection threshold of plain radiograph, and DXA will confirm reduced bone mineral density and guide bisphosphonate dosing
B) Joint aspiration and synovial fluid analysis; the most likely diagnosis is septic arthritis from an opportunistic organism related to her immunosuppressed state, and synovial fluid culture is mandatory before initiating any other imaging
C) Repeat plain radiograph in 6 weeks; steroid-induced hip changes are not visible on initial imaging but become apparent within 6 to 8 weeks as bone resorption progresses, and early MRI is not cost-effective before this window has passed
D) MRI of the right hip; chronic corticosteroid use is a leading cause of avascular necrosis (osteonecrosis) of the femoral head occurring in up to 15% of transplant recipients on long-term steroids, and MRI is highly sensitive for early avascular necrosis — detecting subchondral marrow signal changes before structural collapse occurs — whereas plain radiograph is insensitive in early disease and a normal result does not exclude the diagnosis
E) Bone scan (technetium-99m scintigraphy); avascular necrosis of the femoral head produces a characteristic hot spot on bone scan within the first 2 weeks of symptom onset, and bone scan is more sensitive than MRI in the acute phase of avascular necrosis when marrow signal changes have not yet developed
ANSWER: D
Rationale:
This vignette illustrates one of the most important diagnostic points in transplant medicine regarding steroid-related bone toxicity: a normal plain radiograph does not exclude early avascular necrosis (AVN), and MRI is the required investigation when AVN is clinically suspected. AVN of the femoral head occurs in up to 15% of transplant recipients on chronic corticosteroids, with the femoral head being the most commonly affected site due to its end-arterial blood supply. Early AVN produces characteristic subchondral marrow signal changes (low signal on T1-weighted, high signal on T2-weighted or STIR sequences) that are highly sensitive on MRI before any structural collapse occurs. Plain radiographs become abnormal only after subchondral fracture or femoral head collapse — at which point joint-preserving interventions such as core decompression are no longer feasible. Any transplant recipient on chronic steroids reporting hip, shoulder, or knee pain should have MRI performed even with a normal plain radiograph. Early diagnosis allows timely referral to orthopedics for core decompression, which can prevent progression to femoral head collapse and joint replacement in selected patients.
Option A: Option A is incorrect: while steroid-induced osteoporosis is a real concern in this patient and DXA should be performed as part of longitudinal monitoring, the acute presentation with unilateral groin pain worsening with weight-bearing for 7 weeks is more consistent with AVN than with an insufficiency fracture. DXA does not diagnose AVN.
Option B: Option B is incorrect: septic arthritis presents acutely with fever, joint swelling, warmth, and systemic signs of infection — not with 7 weeks of gradually worsening exertional hip pain in an afebrile patient. While opportunistic infections must always be considered in immunosuppressed patients, the clinical pattern here is far more consistent with AVN.
Option C: Option C is incorrect: waiting 6 weeks for repeat radiography in a patient with progressive weight-bearing pain and a strong clinical risk factor (chronic steroids) is inappropriate. The benefit of early AVN diagnosis — enabling core decompression before structural collapse — is lost if diagnosis is delayed by an additional 6 weeks of observation with an insensitive imaging modality.
Option E: Option E is incorrect: bone scintigraphy has historically been used to detect AVN, but MRI has largely replaced it as the gold standard due to superior sensitivity and specificity. Early AVN may actually produce a cold spot (reduced uptake from vascular compromise) rather than a hot spot on bone scan, and MRI provides superior anatomical detail for staging and surgical planning.
7. A 55-year-old kidney transplant recipient was converted from standard tacrolimus to a reduced-dose tacrolimus plus sirolimus regimen 5 months ago for CNI minimization. He now presents with a 3-week history of progressive dyspnea on exertion, dry cough, and bilateral ankle edema. Fasting triglycerides are 480 mg/dL (up from 180 mg/dL before conversion). Chest X-ray shows bilateral interstitial infiltrates. His sirolimus trough is 9 ng/mL (target 4 to 12 ng/mL). Spirometry shows a restrictive pattern. Infectious workup including BAL (bronchoalveolar lavage) is negative. Which of the following best identifies the underlying etiology and the appropriate management?
A) The constellation of pulmonary infiltrates with a restrictive pattern, bilateral edema, and severe hypertriglyceridemia on a therapeutic sirolimus level in a patient without an infectious etiology represents sirolimus-induced pneumonitis — a class-specific adverse effect of mTOR inhibitors occurring in 3 to 11% of patients; sirolimus should be discontinued and the patient evaluated for an alternative immunosuppressive regimen
B) The bilateral infiltrates, edema, and dyspnea represent volume overload from CNI nephrotoxicity causing nephrotic syndrome; the hypertriglyceridemia reflects hepatic lipoprotein overproduction driven by reduced oncotic pressure from nephrotic-range proteinuria; diuresis and ACE inhibitor therapy are indicated without changing the sirolimus dose
C) The restrictive spirometry pattern with bilateral infiltrates in an immunosuppressed patient is diagnostic of Pneumocystis jirovecii pneumonia (PJP); the negative BAL is a false negative because PJP is notoriously difficult to detect on BAL in patients on immunosuppressive regimens; empirical TMP-SMX therapy should be initiated immediately without discontinuing sirolimus
D) The clinical picture represents tacrolimus-induced interstitial nephritis with pulmonary manifestations; the bilateral infiltrates are immune complex deposits from tacrolimus-specific antibodies, and both tacrolimus and sirolimus should be discontinued while systemic corticosteroids are initiated to reverse the immune complex pulmonary injury
E) The hypertriglyceridemia at this level represents familial hypertriglyceridemia exacerbated by post-transplant weight gain; the pulmonary infiltrates are unrelated and most likely represent a community-acquired atypical pneumonia; azithromycin should be initiated and the sirolimus continued at the current dose
ANSWER: A
Rationale:
This vignette presents a classic cluster of mTOR inhibitor adverse effects that together establish the diagnosis of sirolimus-induced pneumonitis. The key elements are: (1) pulmonary infiltrates with restrictive spirometry in a patient 5 months after conversion to sirolimus; (2) negative infectious workup including BAL, excluding opportunistic and community-acquired infection; (3) severe hypertriglyceridemia — a recognized metabolic adverse effect of mTOR inhibitors that is more pronounced than with CNIs; and (4) bilateral peripheral edema — another recognized mTOR inhibitor adverse effect. Sirolimus-induced pneumonitis occurs in approximately 3 to 11% of patients and spans a spectrum from asymptomatic radiographic infiltrates to severe organizing pneumonia or alveolar hemorrhage. The mechanism involves mTOR inhibitor effects on immune cell trafficking and inflammatory cytokine production in the lung. Any new respiratory symptoms in an mTOR inhibitor-treated patient with a negative infectious workup must prompt consideration of drug-induced pneumonitis and discontinuation of the mTOR inhibitor, with expected resolution of infiltrates and symptoms.
Option B: Option B is incorrect: nephrotic syndrome presents with heavy proteinuria, hypoalbuminemia, and generalized edema — not primarily with bilateral pulmonary infiltrates and a restrictive spirometric pattern. CNI nephrotoxicity does not cause nephrotic syndrome. The constellation described is not consistent with this diagnosis.
Option C: Option C is incorrect: while PJP is an important diagnosis to consider in immunosuppressed patients, BAL has high sensitivity for PJP and a negative result substantially reduces its likelihood. More importantly, the cluster of mTOR inhibitor-specific adverse effects (pneumonitis, hypertriglyceridemia, edema) provides a coherent alternative explanation that requires drug discontinuation regardless of any concurrent infectious consideration.
Option D: Option D is incorrect: tacrolimus does not cause pulmonary immune complex deposition. There is no established mechanism by which tacrolimus produces antibody-mediated pulmonary injury, and "tacrolimus-specific antibodies" causing pulmonary infiltrates is not a recognized clinical entity.
Option E: Option E is incorrect: the degree of hypertriglyceridemia (480 mg/dL with a baseline of 180 mg/dL and no prior diagnosis of familial hypertriglyceridemia) strongly implicates sirolimus as the causative agent — mTOR inhibitors characteristically cause severe hypertriglyceridemia. Dismissing both the hypertriglyceridemia and the pulmonary infiltrates as coincidental findings while continuing sirolimus would miss the diagnosis of drug-induced pneumonitis.
8. A 29-year-old CMV-seronegative (R−) woman receives a kidney transplant from a CMV-seropositive deceased donor (D+). She is started on basiliximab induction, followed by tacrolimus, MMF, and prednisone. At her 2-week post-transplant visit, the covering resident notices that no antiviral prophylaxis has been prescribed. The infectious disease consultant is paged. Which of the following best identifies the correct prophylaxis agent, the rationale for its use in this serological combination, and the standard duration?
A) Acyclovir is the agent of choice for CMV prophylaxis in D+/R− kidney transplant recipients; it is preferred over valganciclovir because it has no myelosuppressive effects, and the standard prophylaxis duration in this high-risk combination is 3 months post-transplant
B) No antiviral prophylaxis is required for D+/R− kidney transplant recipients maintained on tacrolimus-based immunosuppression because tacrolimus inhibits CMV DNA polymerase through its calcineurin inhibitory mechanism, providing sufficient antiviral activity to prevent primary CMV infection from donor-derived virus in the allograft
C) Valganciclovir is the agent of choice; in the D+/R− combination, the seronegative recipient has no CMV-specific T-cell memory and faces risk of primary CMV infection from latent virus in the donor organ reactivating under the recipient's immunosuppressed state; the standard prophylaxis duration is at least 6 months post-transplant for this highest-risk serological pairing
D) Valacyclovir is appropriate for CMV prophylaxis in D+/R− recipients; it prevents CMV reactivation by inhibiting the viral thymidine kinase required for CMV DNA synthesis, and the standard duration is 12 months because the risk of primary CMV infection from donor-derived virus persists for the life of the allograft
E) Prophylaxis is indicated only if the recipient subsequently receives ATG induction or pulse methylprednisolone for rejection; basiliximab induction does not significantly deplete T cells and therefore does not require CMV prophylaxis even in the D+/R− combination, which carries low primary infection risk
ANSWER: C
Rationale:
The D+/R− serological combination — seropositive donor and seronegative recipient — is the highest-risk category for post-transplant CMV disease. The donor organ harbors latent CMV that can reactivate under the recipient's immunosuppressed state. Because the recipient has no pre-existing CMV-specific immune memory (no prior CMV infection, no CMV-specific T cells or antibodies), primary CMV infection from reactivated donor virus can progress rapidly to CMV viremia and end-organ disease (pneumonitis, colitis, retinitis, hepatitis). Valganciclovir — the oral prodrug of ganciclovir — is the standard antiviral prophylaxis agent for CMV in solid organ transplant recipients. It is activated intracellularly by CMV-encoded UL97 kinase and then by cellular kinases to the triphosphate form, which competitively inhibits CMV DNA polymerase. For the D+/R− combination, current guidelines (KDIGO, AST-IDCOP) recommend valganciclovir prophylaxis for a minimum of 6 months post-transplant — a longer duration than the 3 months used for lower-risk CMV combinations — reflecting the higher baseline risk and slower CMV-specific immune reconstitution in this serological pairing.
Option A: Option A is incorrect: acyclovir is effective against herpes simplex and varicella-zoster viruses but has minimal activity against CMV because CMV lacks a thymidine kinase with sufficient acyclovir phosphorylation activity. Ganciclovir and valganciclovir are the agents active against CMV.
Option B: Option B is incorrect: tacrolimus has no antiviral mechanism and does not inhibit CMV DNA polymerase. Calcineurin inhibition is a T-cell-specific immunosuppressive mechanism with no direct antiviral activity. CMV prophylaxis is required in D+/R− recipients regardless of the immunosuppressant used.
Option D: Option D is incorrect: valacyclovir (the prodrug of acyclovir) has limited CMV activity and is not the standard agent for CMV prophylaxis in the D+/R− solid organ transplant setting. Valganciclovir (the prodrug of ganciclovir) is the correct drug. The mechanism attribution — viral thymidine kinase inhibition — describes herpesvirus drugs, not ganciclovir's mechanism, which involves UL97 kinase-dependent phosphorylation.
Option E: Option E is incorrect: the D+/R− serological combination carries high primary CMV infection risk regardless of the induction agent. Basiliximab does not deplete T cells, but this does not negate the requirement for CMV prophylaxis — the risk comes from the absence of donor-specific immune memory in the recipient, not solely from the degree of induction immunosuppression.
9. A 52-year-old kidney transplant recipient at 9 weeks post-transplant develops a rising serum creatinine from 1.5 to 2.8 mg/dL over 5 days. Allograft biopsy shows lymphocytic tubulitis and interstitial infiltration without vascular involvement — consistent with Banff Grade I acute cellular rejection. No donor-specific antibodies are detected and C4d staining is negative. He is treated with intravenous pulse methylprednisolone 500 mg daily for 3 consecutive days. At day 5 after the start of pulse steroids his creatinine has risen further to 3.1 mg/dL. Which of the following is the most appropriate next step?
A) Repeat the pulse methylprednisolone course at a higher dose of 1,000 mg daily for 5 days; a second steroid pulse at higher dose rescues approximately 70% of cases that do not respond to the first pulse and is the standard second-line therapy before lymphocyte-depleting agents
B) Initiate plasmapheresis and intravenous immunoglobulin (IVIG) at 2 g/kg; the absence of C4d staining on the initial biopsy does not exclude antibody-mediated rejection, and the steroid non-response pattern is characteristic of evolving antibody-mediated rather than cellular rejection requiring humoral-directed therapy
C) Increase tacrolimus dose to achieve a trough of 18 to 20 ng/mL; steroid-resistant Banff Grade I rejection reflects inadequate baseline calcineurin inhibition, and supratherapeutic tacrolimus concentrations sufficient to overcome the rejection episode are the established rescue strategy before considering lymphocyte depletion
D) Perform an urgent repeat biopsy before changing therapy; steroid resistance at day 5 mandates histological reclassification because the initial Banff Grade I diagnosis was almost certainly incorrect and the true rejection grade is likely Grade III, which requires a different treatment algorithm
E) Initiate rabbit anti-thymocyte globulin (ATG); failure of creatinine to improve within 3 to 5 days of pulse methylprednisolone defines steroid-resistant acute cellular rejection, for which ATG — a polyclonal T-cell-depleting antibody preparation — is the standard second-line therapy; pre-medicate with corticosteroids, antihistamines, and acetaminophen for cytokine release syndrome
ANSWER: E
Rationale:
Steroid-resistant acute cellular rejection (ACR) is defined as failure of the serum creatinine to improve — or continued worsening — within 3 to 5 days of a full course of pulse methylprednisolone. In this patient, creatinine has risen further at day 5 despite pulse steroids, meeting the definition. Standard of care for steroid-resistant ACR is lymphocyte-depleting therapy with rabbit anti-thymocyte globulin (rATG, thymoglobulin). ATG is a polyclonal preparation derived from rabbits immunized with human thymocytes, containing antibodies against multiple T-cell surface antigens (CD3, CD4, CD8, CD25, CD28, CD45). It causes profound T-cell depletion through complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). Because ATG infusion causes cytokine release syndrome — fever, rigors, hypotension — pre-medication with corticosteroids, antihistamines (diphenhydramine), and acetaminophen is required before each infusion. ATG is given as daily infusions for 3 to 7 days depending on clinical response.
Option A: Option A is incorrect: a second pulse of higher-dose methylprednisolone is not standard of care for steroid-resistant ACR. Once a full pulse course has failed over 3 to 5 days, escalating to a higher steroid dose does not reliably rescue the rejection episode and delays definitive lymphocyte-depleting therapy while the allograft continues to be damaged.
Option B: Option B is incorrect: the biopsy shows Banff Grade I cellular rejection (tubulitis and interstitial infiltration) with negative donor-specific antibodies and negative C4d — the diagnostic triad of antibody-mediated rejection is absent. Treating this presentation with plasmapheresis and IVIG without evidence of AMR would be inappropriate.
Option C: Option C is incorrect: supratherapeutic tacrolimus concentrations of 18 to 20 ng/mL are nephrotoxic — they would add acute functional nephrotoxicity to an already damaged kidney and are not the standard management of steroid-resistant ACR. Dose escalation to these levels is not an evidence-based rescue strategy.
Option D: Option D is incorrect: steroid resistance at day 5 does not mandate repeat biopsy before proceeding. While biopsy is important in the diagnostic workup, the established treatment algorithm proceeds to ATG after confirmed steroid resistance without requiring repeat biopsy to reclassify the rejection grade first. The initial Grade I diagnosis is consistent with the clinical response pattern.
10. A 26-year-old woman who received a kidney transplant 2 years ago presents to a dermatology consultation for increasing facial and body hair growth that began approximately 6 months after transplant, and progressive gum overgrowth that her dentist has noted over the past year. She is distressed about both changes. Her current immunosuppression record from the transplant center is unavailable, but she brings a medication bottle. The dermatologist, familiar with transplant medications, recognizes that this specific cosmetic adverse effect profile — hirsutism combined with gingival hyperplasia — identifies her calcineurin inhibitor. Which calcineurin inhibitor is she most likely taking, and what would be expected if she were switched to the other agent?
A) She is most likely taking tacrolimus; tacrolimus causes both hirsutism and gingival hyperplasia through its FKBP-12 pathway in dermal follicles and gingival fibroblasts; switching to cyclosporine would eliminate both cosmetic effects because cyclosporine does not affect hair growth or gingival tissue
B) She is most likely taking cyclosporine; cyclosporine is the calcineurin inhibitor associated with both hirsutism (excess hair growth) and gingival hyperplasia (gum overgrowth); switching to tacrolimus would be expected to eliminate the hirsutism — tacrolimus causes alopecia rather than excess hair growth — and would reduce gingival hyperplasia, though resolution may be incomplete and dental evaluation would still be required
C) She is most likely taking tacrolimus; the hirsutism reflects elevated androgen levels caused by tacrolimus-mediated inhibition of androgen oxidase in the adrenal cortex, while the gingival hyperplasia reflects tacrolimus-induced overstimulation of gingival fibroblast collagen synthesis; both resolve within 4 weeks of switching to cyclosporine
D) The cosmetic profile described — hirsutism and gingival hyperplasia — cannot be attributed to either calcineurin inhibitor because both cyclosporine and tacrolimus produce identical cosmetic adverse effects through the same calcineurin inhibitory mechanism in dermal and gingival tissues
E) She is most likely taking sirolimus; mTOR inhibitor-induced mTORC1 hyperactivation in gingival fibroblasts and androgenic dermal papillae occurs when mTORC1 is partially but not fully inhibited at therapeutic sirolimus concentrations, producing the described cosmetic effects; dose reduction to achieve lower mTOR inhibition would paradoxically worsen both conditions
ANSWER: B
Rationale:
The combination of hirsutism and gingival hyperplasia is the characteristic cosmetic adverse effect profile of cyclosporine — not tacrolimus. Cyclosporine causes hirsutism (excess hair growth, particularly on the face, arms, and body) and gingival hyperplasia (overgrowth of gum tissue that can become severe enough to cover the teeth and require gingivectomy) in a substantial proportion of treated patients. These effects are thought to involve cyclosporine-mediated alterations in dermal growth factor signaling and gingival fibroblast collagen turnover. Tacrolimus produces opposite cosmetic effects on hair — alopecia (hair loss or thinning) rather than hirsutism — and causes significantly less gingival hyperplasia. Identifying this cosmetic profile from a medication bottle or patient report is clinically useful: the combination of hirsutism plus gingival hyperplasia identifies the patient as being on cyclosporine with high specificity. If switched to tacrolimus, the hirsutism would be expected to resolve (and the patient might experience some degree of hair thinning instead) and the gingival hyperplasia would typically improve, although some residual gingival changes may persist and dental management is still advisable.
Option A: Option A is incorrect: tacrolimus does not cause hirsutism or gingival hyperplasia. These cosmetic effects are specifically associated with cyclosporine. Tacrolimus causes alopecia, not hirsutism, and has significantly lower rates of gingival hyperplasia.
Option C: Option C is incorrect: the cosmetic profile described identifies cyclosporine, not tacrolimus. Tacrolimus does not cause hirsutism. The mechanism attribution — androgen oxidase inhibition — is not an established mechanism for either CNI, and the claim that effects resolve in 4 weeks of switching is not accurate for gingival hyperplasia.
Option D: Option D is incorrect: cyclosporine and tacrolimus have distinctly different cosmetic adverse effect profiles despite sharing calcineurin as their downstream target. These differences are well established clinically and are relevant to drug selection.
Option E: Option E is incorrect: sirolimus is an mTOR inhibitor, not a calcineurin inhibitor, and is not associated with the hirsutism-gingival hyperplasia combination described. mTOR inhibitor adverse effects include oral mucositis, edema, hypertriglyceridemia, and pneumonitis — not hirsutism or gingival hyperplasia.
11. A 61-year-old kidney transplant recipient underwent transplantation 7 weeks ago. His post-operative course was initially uncomplicated, with a well-healing incision at his 4-week visit. At 5 weeks post-transplant, his tacrolimus was reduced and sirolimus was added for CNI minimization given mild early creatinine concerns. He now presents at 7 weeks with a partially dehisced (separated) abdominal incision with serous drainage, bilateral lower extremity pitting edema, and a fluid collection on ultrasound adjacent to the allograft consistent with a lymphocele. His sirolimus trough is 7 ng/mL. Tacrolimus trough is 4 ng/mL. Which of the following best explains the mechanism underlying his wound complications and the error in clinical management?
A) The bilateral edema and lymphocele reflect over-immunosuppression from the combined sirolimus and tacrolimus regimen causing a capillary leak syndrome similar to cytokine release syndrome; the combined calcineurin and mTOR inhibition exceeds the threshold for endothelial stability, and both drugs should be discontinued simultaneously and replaced with MMF monotherapy
B) Sirolimus caused wound dehiscence and lymphocele formation by inhibiting platelet mTORC1, reducing thromboxane A2-mediated platelet aggregation and impairing the initial hemostatic phase of wound healing; this antiplatelet mechanism is the primary reason sirolimus is avoided in the early post-operative period
C) The lymphocele and wound dehiscence reflect inadequate immunosuppression from the low tacrolimus trough of 4 ng/mL; subclinical rejection is causing local inflammatory cytokine release that disrupts wound healing and lymphatic integrity; tacrolimus should be increased immediately to a trough of 12 to 15 ng/mL
D) Sirolimus was initiated too early — at 5 weeks post-transplant, before surgical wound healing was complete; mTOR inhibitors suppress fibroblast proliferation and collagen deposition by blocking mTORC1-driven protein synthesis in fibroblasts, impairing the repair process required for wound closure; standard practice is to defer mTOR inhibitor initiation for at least 4 to 12 weeks post-transplant until surgical healing is confirmed, and sirolimus should be discontinued and the patient managed for wound and lymphocele complications
E) The wound dehiscence and lymphocele represent a foreign body reaction to the surgical suture material used at transplantation; sirolimus has no role in wound healing and the edema reflects renal artery stenosis at the anastomosis causing hypertension-driven fluid retention that should be evaluated with Doppler ultrasound of the renal vasculature
ANSWER: D
Rationale:
This vignette illustrates the clinical consequence of initiating an mTOR inhibitor before surgical wound healing is complete. Sirolimus and everolimus inhibit mTORC1 in fibroblasts — the cells responsible for the proliferative phase of wound healing, during which they migrate into the wound bed, proliferate, synthesize collagen, and close the wound. mTORC1 inhibition blocks the protein synthesis required for fibroblast proliferation and collagen deposition, impairing wound repair. In this patient, sirolimus was started at 5 weeks post-transplant while the incision was still in active repair. The resulting wound dehiscence reflects impaired fibroblast-mediated closure. The lymphocele — a fluid collection from inadequately sealed lymphatics adjacent to the allograft — occurs because mTOR inhibitors also impair the sealing of surgically disrupted lymphatic channels, which requires fibroblast and myofibroblast activity. The bilateral edema is another recognized peripheral adverse effect of mTOR inhibitors. Standard practice is to defer mTOR inhibitor initiation for at least 4 to 12 weeks post-transplant and after any major surgery until wound healing is confirmed. Management requires discontinuing sirolimus, reverting to standard-dose tacrolimus if needed for immunosuppression, and surgical or interventional management of the lymphocele if symptomatic.
Option A: Option A is incorrect: the combination of sirolimus and tacrolimus does not cause cytokine release syndrome or a capillary leak syndrome equivalent. The wound and lymphocele complications are explained by mTOR inhibitor-mediated fibroblast suppression, not by vascular leak from combined immunosuppression.
Option B: Option B is incorrect: sirolimus does not cause wound complications primarily through platelet mTORC1 inhibition and reduced thromboxane A2. The established mechanism is fibroblast proliferation and collagen synthesis impairment — not an antiplatelet effect on hemostasis.
Option C: Option C is incorrect: the wound dehiscence and lymphocele are drug-related complications of sirolimus — not consequences of inadequate immunosuppression from low tacrolimus. Increasing tacrolimus to supratherapeutic levels would add nephrotoxicity without addressing the underlying mTOR inhibitor wound toxicity.
Option E: Option E is incorrect: foreign body reactions to suture material do not typically cause dehiscence at 7 weeks, bilateral peripheral edema, or lymphocele formation. Sirolimus has a well-established and clinically critical role in impairing wound healing, and attributing all findings to unrelated causes would miss the drug-related diagnosis.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.